+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Dyslipidemia Disease Analysis and Market and Forecast Analysis 2024

  • ID: 4775188
  • Report
  • June 2018
  • Region: Global
  • 546 pages
  • Datamonitor Healthcare
1 of 2

Enquire about COVID-19 updates for this product.

Enquire Now
Disease Overview
Dyslipidemia refers to any increase or decrease in lipid levels from defined normal parameters, with physicians particularly focusing on the treatment of elevated LDL-C due to the well-established link between excessively elevated LDL-C and atherosclerosis. As such, LDL-C is a major modifiable risk factor for cardiovascular disease, one of the world’s leading causes of morbidity and mortality. Other lipid level deviations in dyslipidemia include low levels of HDL-C, elevated total cholesterol, and elevated triglycerides.

Market Snapshot
  • Generic erosion of key legacy product sales will be offset by the growth of the branded PCSK9 inhibitor class.
  • The author’s primary research survey of 238 physicians sheds light on prescribing patterns in dyslipidemia.
  • Dyslipidemia is a serious public health concern, as prevalence is high and it is a strong risk factor for CVD and CAD.
  • Positive CVOT data combined with steep discounts will drive PCSK9 uptake.
  • Inclisiran is a promising pipeline medication and has the opportunity to provide cost-effective PCSK9 inhibition.
  • Payers impose strict access controls on PCSK9 inhibitors.
Note: Product cover images may vary from those shown
2 of 2
FORECAST: DYSLIPIDEMIA (Published on 22 June 2018)
Overview
Recent Forecast Updates
Market Dynamics
Forecast And Future Trends
Market Definition And Methodology
Primary Research Methodology
Bibliography
Product Profile: Crestor
Product Profile: Juxtapid
Product Profile: Kynamro
Product Profile: Lipitor
Product Profile: Praluent
Product Profile: Repatha
Product Profile: Zetia Franchise
Product Profile (Late Stage): Bempedoic Acid Franchise
Product Profile (Late Stage): Evinacumab
Product Profile (Late Stage): Inclisiran
Product Profile (Late Stage): Volanesorsen

TREATMENT: DYSLIPIDEMIA (Published on 19 June 2017)
Overview
Executive Summary
Primary Research Methodology
Disease Definition And Diagnosis
Patient Segmentation
Prescribing Trends
Unmet Needs In Dyslipidemia

EPIDEMIOLOGY: HYPERCHOLESTEROLEMIA AND DYSLIPIDEMIA (Published on 07 June 2018)
Overview
Disease Background
Methodology
Forecast
Supplementary Analysis: Dyslipidemia In The Us
Bibliography
Appendix: Additional Sources

MARKETED DRUGS: DYSLIPIDEMIA (Published on 22 June 2018)
Overview
Statins
Pcsk9 Inhibitors
Fibrates
Niacins
Omega-3 Fatty Acids
Other Drug Classes
Product Profile: Crestor
Product Profile: Epanova
Product Profile: Juxtapid
Product Profile: Kynamro
Product Profile: Lipitor
Product Profile: Lovaza
Product Profile: Praluent
Product Profile: Repatha
Product Profile: Vascepa
Product Profile: Zetia Franchise

PCSK9 INHIBITORS PRICING, REIMBURSEMENT, AND ACCESS (Published on 21 December 2016)
Overview
Executive Summary
Payer Insights
Us Pricing
Us Reimbursement
Japan
Five Major EU Markets Pricing
France
Germany
Italy
Spain
Uk
Methodology

PIPELINE: DYSLIPIDEMIA (Published on 22 June 2018)
Overview
Clinical Pipeline Overview
Recently Discontinued Drugs
Additional Pharma Intelligence Pipeline Resources
Product Profile (Late Stage): Bempedoic Acid Franchise
Product Profile (Late Stage): Evinacumab
Product Profile (Late Stage): Inclisiran
Product Profile (Late Stage): Volanesorsen
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll